We are live on ! Find out more
BI

BVF Inc Portfolio holdings

AUM $3.14B
1-Year Est. Return 249.53%
This Fund
S&P 500
This Quarter Est. Return
-2.59%
1 Year Est. Return
+249.53%
3 Year Est. Return
+690.11%
5 Year Est. Return
+1,011.36%
10 Year Est. Return
+22,702.25%
AUM
$3.57B
AUM Growth
-$69.4M
Cap. Flow
+$212M
Cap. Flow %
5.95%
Top 10 Hldgs %
61.01%
Holding
66
New
4
Increased
9
Reduced
7
Closed
6

Top Buys

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$70.7M
2
GPCR icon
Structure Therapeutics
GPCR
+$68.8M
3
CELC icon
Celcuity
CELC
+$58M
4
CGEM icon
Cullinan Oncology
CGEM
+$54.4M
5
AGIO icon
Agios Pharmaceuticals
AGIO
+$43M

Top Sells

Rank Stock Value
1
JANX icon
Janux Therapeutics
JANX
+$116M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$44.6M
3
KURA icon
Kura Oncology
KURA
+$14.5M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$12.8M
5
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$8.35M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
51
Palvella Therapeutics
PVLA
$2.05B
$2.55M 0.07%
257,626
+3
+0% +$34
IVA
52
Inventiva
IVA
$1.06B
$2.02M 0.06%
686,040
– –
VIRX
53
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.97M 0.06%
3,614,662
– –
FBRX icon
54
Forte Biosciences
FBRX
$1.57B
$1.6M 0.04%
119,284
– –
ENGNW icon
55
enGene Therapeutics Warrants
ENGNW
$3.64M
$1.31M 0.04%
945,402
– –
NCEL
56
NewcelX Ltd
NCEL
$18.1M
$1.25M 0.03%
14,368
– –
UNCY icon
57
Unicycive Therapeutics
UNCY
$140M
$1.1M 0.03%
220,000
-141,160
-39% -$1.39M
RZLT icon
58
Rezolute
RZLT
$454M
$821K 0.02%
190,815
– –
MTEM
59
DELISTED
Molecular Templates, Inc.
MTEM
$601K 0.02%
522,238
– –
ASLN
60
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$315K 0.01%
131,250
– –
ANTX icon
61
AN2 Therapeutics
ANTX
$199M
– –
-1,239,470
Closed -$4.03M
CRVS icon
62
Corvus Pharmaceuticals
CRVS
$1.11B
– –
-361,406
Closed -$643K
DCTH icon
63
Delcath Systems
DCTH
$412M
– –
-1,202,067
Closed -$5.73M
KRON
64
DELISTED
Kronos Bio
KRON
– –
-2,905,043
Closed -$3.78M
LXRX icon
65
Lexicon Pharmaceuticals
LXRX
$1.02B
– –
-1,686,924
Closed -$4.05M
SNDX icon
66
Syndax Pharmaceuticals
SNDX
$1.69B
– –
-1,875,000
Closed -$44.6M
1 2
3

Similar funds

GKWIM
Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.14B AUM 22.62% 1-Year Est. Return
BP
BNP Paribas Paris, France $3.15B AUM 22.54% 1-Year Est. Return
LFG
Larson Financial Group St Louis, Missouri $3.13B AUM 22.88% 1-Year Est. Return
DIG
DeepCurrents Investment Group New York $3.12B AUM 12.93% 1-Year Est. Return
CCI
Cevian Capital II St. Helier, Jersey $3.12B AUM 25.62% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
BFA
Bragg Financial Advisors Charlotte, North Carolina $3.16B AUM 26% 1-Year Est. Return

BVF Inc's Q2 2024 Portfolio in Review

As of Q2 2024, BVF Inc held 66 positions worth $3.57B, down 1.9% from $3.64B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

BVF Inc deployed $212M of net new capital in Q2 2024, opening 4 new positions and adding to 9 existing holdings. Its largest new stake was Axsome Therapeutics: 955,000 shares worth $76.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

On the sell side, the largest reduction was Janux Therapeutics, an estimated $116M trimmed.

  • BVF Inc's largest Q2 2024 buy was Axsome Therapeutics: 955,000 shares worth $76.9M.
  • BVF Inc added most to Structure Therapeutics in Q2 2024, an estimated $68.8M increase.
  • BVF Inc's biggest Q2 2024 reduction was Janux Therapeutics, cutting an estimated $116M.
  • BVF Inc fully exited Syndax Pharmaceuticals in Q2 2024, selling an estimated $44.6M.
  • BVF Inc's ten largest holdings make up 61% of its $3.57B portfolio in Q2 2024.
  • BVF Inc opened 4 new positions and closed 6 in Q2 2024.
  • BVF Inc's portfolio value fell 1.9% quarter-over-quarter to $3.57B.

Based on BVF Inc's 13F filing for Q2 2024, filed 14 Aug 2024.